参考文献/References:
[1]Jameson JL,Longo DL.Precision medicine--personalized,problematic,and promising[J].New England Journal of Medicine,2015,372(23):2229-2234.
[2]2018 ASCO: KEYNOTE-042 Trial Compares Pembrolizumab With Chemotherapy as First-Line Treatment of NSCLC With PD-L1 Expression of 1% or More[EB/OL].[2018-03-06].http://www.ascopost.com/News/58902.
[3]Precision Medicine[EB/OL].[2018-04-12].https://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/precisionmedicine-medicaldevices/default.htm.
[4]Daniel Y. Wang,Joe-Elie Salem,Justine V. Cohen,et al.Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors:A Systematic Review and Meta-analysis[J].JAMA Oncol,2018:3923.
[5]Gandhi L,Rodríguez-Abreu D,Gadgeel S,et al.Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer[J].N Engl J Med,2018,378(22):2078-2092.
[6]Alice Goodman.KEYNOTE-407:Pembrolizumab Plus Chemotherapy Benefits Response,Survival in Squamous NSCLC[EB/OL].[2018-07-10].http://www.ascopost.com/issues/july-10-2018/keynote-407-pembrolizumab-plus-chemotherapy-in-squamous-nsclc/.
[7]Du X,Liu M,Su J,et al.Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice[J].Cell Res,2018,28(4):433-447.
[8]Huang Y,Kim BYS,Chan CK,et al.Improving immune-vascular crosstalk for cancer immunotherapy[J].Nat Rev Immunol,2018,18(3):195-203.